Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease

罗替戈汀 运动障碍 左旋多巴 相伴的 医学 帕金森病 安慰剂 透皮贴片 麻醉 内科学 透皮 疾病 药理学 替代医学 病理
作者
Nir Giladi,L. Ghys,Erwin Surmann,Babak Boroojerdi,Joseph Jankovic
出处
期刊:Parkinsonism & Related Disorders [Elsevier BV]
卷期号:20 (12): 1345-1351 被引量:24
标识
DOI:10.1016/j.parkreldis.2014.09.016
摘要

Purpose In two 6-month, double-blind, placebo-controlled studies, rotigotine transdermal system was well-tolerated and efficacious monotherapy in early-stage PD. This post hoc analysis of the long-term open-label extensions (NCT00594165; NCT00599196) of these studies assessed incidence and severity of dyskinesia in participants treated with rotigotine, with or without concomitant levodopa, for up to 6 years. Methods Open-label rotigotine was titrated to optimal dose (≤16 mg/24 h). Concomitant levodopa was permitted. Dyskinesia data, recorded using the Unified Parkinson's Disease Rating Scale Part IV, were pooled from the two open-label studies. Results Of 596 participants who received open-label rotigotine, 299 (50%) remained at trial closure; no patient discontinued due to dyskinesia. In the two studies, median exposure to rotigotine was 1910 days (∼5 years, 3 months), and 1564.5 days (∼4 years, 3 months). During up to 6 years of open-label rotigotine, 423/596 (71%) received levodopa. Dyskinesias were reported in 115/596 (19%) participants, 90/115 (78%) of who developed dyskinesia after levodopa was added; 25 reported dyskinesia in the absence of levodopa (includes patients who never received open-label levodopa, and those who reported dyskinesia before starting concomitant levodopa). Dyskinesia severity data were available for 107 of the 115 participants. In 56/107 (52%) participants, dyskinesia was considered ‘not disabling’ for all occurrences; the worst-case severity was ‘mildly disabling’ for 33/107 (31%), and ‘moderately’ or ‘severely disabling’ for 18/107 (17%; 3% of total participants). Conclusion During treatment with rotigotine in patients with PD for up to 6 years the incidence of dyskinesia was low, and the dyskinesia was generally ‘not disabling’ or ‘mildly disabling’.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Fine发布了新的文献求助10
1秒前
Yuelong完成签到,获得积分10
2秒前
4秒前
dong应助Yuelong采纳,获得10
7秒前
bingsu108完成签到,获得积分10
8秒前
小岚花发布了新的文献求助10
10秒前
CodeCraft应助凉茶采纳,获得10
10秒前
脑洞疼应助YZQ采纳,获得10
11秒前
琳琳完成签到,获得积分10
11秒前
华仔应助俏皮的白柏采纳,获得10
12秒前
羊洋洋完成签到,获得积分20
12秒前
最爱地瓜和虾滑完成签到 ,获得积分10
14秒前
yar给聪慧的草丛的求助进行了留言
14秒前
奋斗雁山发布了新的文献求助10
14秒前
15秒前
查到文献了吗完成签到,获得积分10
15秒前
FashionBoy应助Lee采纳,获得10
15秒前
Elvira完成签到,获得积分10
15秒前
17秒前
19秒前
易酰水烊酸应助Onism采纳,获得10
19秒前
青岚完成签到 ,获得积分10
19秒前
20秒前
tay发布了新的文献求助10
21秒前
22秒前
pluto应助一直小虾米采纳,获得10
22秒前
双楠应助不想采纳,获得10
24秒前
25秒前
Luobing完成签到,获得积分10
26秒前
研友_LXjjOZ完成签到,获得积分10
26秒前
上官若男应助蔚蓝的天空采纳,获得10
27秒前
slr完成签到,获得积分10
27秒前
逆境发布了新的文献求助10
27秒前
28秒前
草莓布丁发布了新的文献求助80
29秒前
凉茶发布了新的文献求助10
30秒前
30秒前
32秒前
32秒前
32秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988838
求助须知:如何正确求助?哪些是违规求助? 3531250
关于积分的说明 11252914
捐赠科研通 3269838
什么是DOI,文献DOI怎么找? 1804820
邀请新用户注册赠送积分活动 881943
科研通“疑难数据库(出版商)”最低求助积分说明 809028